Optimal drug and behavior therapy for treatment-refractory schizophrenic patients

Robert Paul Liberman; Theodore Van Putten; Barringer D. Marshall; Jim Mintz; Linda Bowen; Timothy G. Kuehnel; Manickan Aravagiri; Stephen R. Marder

doi:10.1176/ajp.151.5.756

Optimal drug and behavior therapy for treatment-refractory schizophrenic patients

Robert Paul Liberman, Theodore Van Putten, Barringer D. Marshall, Jim Mintz, Linda Bowen, Timothy G. Kuehnel, Manickan Aravagiri, Stephen R. Marder

Research output: Contribution to journal › Article

34 Scopus citations

Abstract

Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction.

Original language	English (US)
Pages (from-to)	756-759
Number of pages	4
Journal	American Journal of Psychiatry
Volume	151
Issue number	5
DOIs	https://doi.org/10.1176/ajp.151.5.756
State	Published - May 1994
Externally published	Yes

Fingerprint

ASJC Scopus subject areas

Psychiatry and Mental health

Cite this

Liberman, R. P., Van Putten, T., Marshall, B. D., Mintz, J., Bowen, L., Kuehnel, T. G., Aravagiri, M., & Marder, S. R. (1994). Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. American Journal of Psychiatry, 151(5), 756-759. https://doi.org/10.1176/ajp.151.5.756

@article{ed2b1f249fc64921a123cfdc24f166a3,

title = "Optimal drug and behavior therapy for treatment-refractory schizophrenic patients",

abstract = "Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction.",

author = "Liberman, {Robert Paul} and {Van Putten}, Theodore and Marshall, {Barringer D.} and Jim Mintz and Linda Bowen and Kuehnel, {Timothy G.} and Manickan Aravagiri and Marder, {Stephen R.}",

year = "1994",

month = may

doi = "10.1176/ajp.151.5.756",

language = "English (US)",

volume = "151",

pages = "756--759",

journal = "American Journal of Psychiatry",

issn = "0002-953X",

publisher = "American Psychiatric Association",

number = "5",

}

TY - JOUR

T1 - Optimal drug and behavior therapy for treatment-refractory schizophrenic patients

AU - Liberman, Robert Paul

AU - Van Putten, Theodore

AU - Marshall, Barringer D.

AU - Mintz, Jim

AU - Bowen, Linda

AU - Kuehnel, Timothy G.

AU - Aravagiri, Manickan

AU - Marder, Stephen R.

PY - 1994/5

Y1 - 1994/5

N2 - Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction.

AB - Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction.

UR - http://www.scopus.com/inward/record.url?scp=0028202507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028202507&partnerID=8YFLogxK

U2 - 10.1176/ajp.151.5.756

DO - 10.1176/ajp.151.5.756

M3 - Article

C2 - 8166320

AN - SCOPUS:0028202507

VL - 151

SP - 756

EP - 759

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 5

ER -

Access to Document

10.1176/ajp.151.5.756